Company:Duearity

From HandWiki
Revision as of 20:15, 9 February 2024 by TextAI2 (talk | contribs) (change)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Swedish medical products company
Duearity AB
FormerlyCochlearity
TypePublic (Aktiebolag)
ISINSE0015949482
IndustryMedical equipment  ·
Tinnitus treatment
Headquarters
Malmö
,
Sweden
Key people
ProductsTinearity G1
Tinearity AI
Websitewww.duearity.com
Footnotes / references
[1][2][3][4][5][6][7]

Duearity is a Swedish medical technology company based in Malmö. The company specialises in hardware and software for tinnitus treatment. As of May 2021, Duearity is a public company listed on the Nasdaq First North stock exchange.[8][9][10]

Origins

Peter Arndt, one of Duearity's founders, was undergoing tinnitus retraining therapy (TRT) and noticed the treatment to be effective, but incompatible with daily life. Tinnitus retraining therapy is based on cognitive behavioral therapy and requires white noise to be played uninterrupted for 6-8 hours per day for 6-24 months. Wearing headphones for prolonged and uninterrupted period of time was interfering with work during daytime and with sleep during nighttime.

The founders set out to find a solution that did not require headphones and did not occupy the ear canals.[11][12][1] In 2020, a proof of concept was successfully completed and the company applied for a patent.[13][14]

IPO

On 11 May 2021, the company's shares debuted on Nasdaq First North under ticker symbol DEAR. The company was previously called Cochlearity, but the name was changed pre-IPO in order to avoid mixup with another medtech company.[15]

75,3% of the IPO shares were subscribed before the IPO offer was made public.[16][17] Duearity’s IPO was oversubscribed by 9 times.[18]

Products and market

Duearity is focusing its products on white noise and tinnitus retraining therapy, which has been shown to be effective in a variety of research studies.[19][20][21][22]

Since 2020, Duearity has been developing the world's smallest and most flexible tinnitus aid that emits white noise through bone conduction technology.[23][24] It is a patented medtech CE class IIa product.[25][26] It is a non-invasive device that attaches behind the ears and keeps the ear canals free. The device will be launched in Europe once it receives a CE marking[27] and in the USA once it receives FDA approval.[28]

Duearity is also developing a software for analysing tinnitus and managing its symptoms.[29] The company observes strong interest from researchers, audiologists and otorhinolaryngologists.[14] As of 2022, it is not yet available on the market.[30]

References

  1. ↑ 1.0 1.1 Annual Report 2021: arsredovisning-2021-duearity-ab-signerad.pdf , accessdate: 6 december 2022
  2. ↑ MedTech Magazine: Cochlearity blir Duearity inför börsnotering - MedTech Magazine , accessdate: 6 december 2022
  3. ↑ Nasdaq: DEAR, Duearity, (SE0015949482) - Nasdaq , accessdate: 6 december 2022
  4. ↑ Bolagsverket: Sök företagsinformation Företag - Sök företagsinformation, accessdate: 6 december 2022
  5. ↑ Skatteverket: Duearity AB | Skatteverket , accessdate: 6 december 2022
  6. ↑ The Wall Street Journal : Duearity DEAR.SE | Duearity AB Financial Statements - WSJ , accessdate: 6 december 2022
  7. ↑ "Duearity Aktie" (in sv). Dagens industri. 2022-12-15. https://www.di.se/bors/aktier/dear-5441090/. 
  8. ↑ Nasdaq: Listing of Duearity AB (publ), on Nasdaq First North Growth Market (203/21) | Nasdaq, accessdate: 6 december 2022
  9. ↑ Hörselbolaget Duearity till First North: Hörselbolaget Duearity till First North , accessdate: 6 december 2022
  10. ↑ Affärsvärlden: Duearity - IPO | Affärsvärlden , accessdate: 6 december 2022
  11. ↑ Digital Health Technology News: Swedish MedTech startup starts pre-sale of unique product for tinnitus treatment - Digital Health Technology News , accessdate: 6 december 2022
  12. ↑ MedTech Magazine: Malmöbolag lanserar produkt för egenbehandling av tinnitus - MedTech Magazine , accessdate: 6 december 2022
  13. ↑ "Duearity AB:s halvårsrapport för perioden 1 januari till 30 juni 2021" (in sv). 2021-08-25. https://view.news.eu.nasdaq.com/view?id=b3b414d08e5307c8a205ae0af800d7661&lang=sv. 
  14. ↑ 14.0 14.1 "Duearity 2022 Q3" (in sv). https://storage.mfn.se/0352446f-2290-4fd0-bdce-7542b5443896/q3-2022-duearity-ab.pdf. 
  15. ↑ MedTech Magazine: Cochlearity blir Duearity inför börsnotering - MedTech Magazine , accessdate: 6 december 2022
  16. ↑ "IPO Guide: Duearity". Affärsvärlden. https://www.affarsvarlden.se/ipo-guiden/bolag/duearity. 
  17. ↑ Liedholm, Kim (2021-04-20). "Duearity vill hjälpa personer med tinnitusbesvär" (in sv). https://www.biostock.se/2021/04/duearity-vill-hjalpa-personer-med-tinnitusbesvar/. 
  18. ↑ "Duearitys emission kraftigt övertecknad" (in sv). 2021-04-30. https://www.dagensps.se/bors-finans/borsnoteringar/duearitys-emission-kraftigt-overtecknad/. 
  19. ↑ "Clinical efficacy of tinnitus retraining therapy and cognitive behavioural therapy in the treatment of subjective tinnitus: a systematic review". J Laryngol Otol 128 (12): 1028–33. December 2014. doi:10.1017/S0022215114002849. PMID 25417546. 
  20. ↑ "The effect of tinnitus retraining therapy on chronic tinnitus: A controlled trial". Laryngoscope Investig Otolaryngol 2 (4): 166–177. August 2017. doi:10.1002/lio2.76. PMID 28894836. 
  21. ↑ "Tinnitus retraining therapy: prognosis factors". Am J Otolaryngol 28 (4): 225–9. 2007. doi:10.1016/j.amjoto.2006.09.004. PMID 17606035. 
  22. ↑ "Efficacy of tinnitus retraining therapy in the treatment of tinnitus: A meta-analysis and systematic review". Am J Otolaryngol 42 (6): 103151. 2021. doi:10.1016/j.amjoto.2021.103151. PMID 34303210. 
  23. ↑ BioStock: Duearity vill hjälpa personer med tinnitusbesvär - BioStock , accessdate: 6 december 2022
  24. ↑ Duearity ska noteras på Nasdaq First North den 11 maj: Duearity ska noteras på Nasdaq First North den 11 maj , accessdate: 6 december 2022
  25. ↑ Svensk Patentdatabas, Träfflista: Svensk Patentdatabas, Träfflista , accessdate: 6 december 2022
  26. ↑ PRV avser att godkänna Duearitys patentansökan: PRV avser att godkänna Duearitys patentansökan , accessdate: 6 december 2022
  27. ↑ Duearitys produkt beräknas erhålla CE-märkning i november i år: Duearitys produkt beräknas erhålla CE-märkning i november i år , accessdate: 6 december 2022
  28. ↑ Investeringsmemorandum-Duearity-AB-2022.pdf: investerarmemorandum.indd - Investeringsmemorandum-Duearity-AB-2022.pdf , accessdate: 6 december 2022
  29. ↑ "Swedish Patent Database, Results list". 2020-07-27. https://tc.prv.se/spd/search?content=&number=544905&numberflag=&klass=&from=&to=&dateflag=&prionr=&applicant=&inventor=&representative=&cityzip=&cityzipflag=&tidnrtyp=&tidar_from=&tidnr_from=&tidar_tom=&tidnr_tom=&inforce=&system=&lang=en&hits=true&tab=2. 
  30. ↑ Inderes: Osakeanalyysit, mallisalkku, osakevertailu & aamukatsaus: Duearity to develop AI solution for people suffering from tinnitus | Inderes: Osakeanalyysit, mallisalkku, osakevertailu & aamukatsaus , accessdate: 6 december 2022

External links

Further reading

See also



Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Duearity&oldid=3482992"